Posts by: David Melamed, PhD

David Melamed, PhD

David holds a PhD in Biological Sciences from Columbia University in New York, NY, where he studied how Drosophila ovarian adult stem cells respond to cell signaling pathway manipulations. As a Graduate Student and Postdoctoral Fellow at Columbia, his work helped redefine the organizational principles underlying adult stem cell growth models. He is currently a Science Writer, as part of the BioNews Services writing team.

October 9, 2020October 9, 2020

Libra Therapeutics Launches With Pipeline of 3 ALS Treatment Candidates

News

Libra Therapeutics has officially announced its launch with a platform dedicated to developing new treatments for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The company also ... Read more

September 25, 2020September 30, 2020

University of Sheffield Partners With Aclipse to Advance ALS Treatment M102 to Clinical Trial

News

M102, a potential treatment for amyotrophic lateral sclerosis (ALS), is advancing into its first clinical study in patients through a partnership between researchers at England’s University of Sheffield Institute for ... Read more

September 24, 2020September 24, 2020

Japan Grants Patent to Brainstorm Covering Technique for NurOwn

News

The Japan Patent Office has granted a patent to Brainstorm Cell Therapeutics covering the proprietary technique that generates the company’s cell-based therapy NurOwn from mesenchymal stem cells (MSCs). Through ... Read more

September 14, 2020September 14, 2020

PrimeC Shows Potential to Slow ALS Progression, Interim Data Reveal

News

PrimeC is safe and well-tolerated for the treatment of amyotrophic lateral sclerosis (ALS) and shows potential to slow disease progression and lung function decline, according to interim results from ... Read more

August 18, 2020August 18, 2020

Inhibition of RAGE Protein Lessens ALS Symptoms in Mice, Study Finds

News

Inhibiting the receptor for advanced glycation end products (RAGE) protein lessens the symptoms of amyotrophic lateral sclerosis (ALS), according to a study in mice. However, a full deletion of the ... Read more

August 12, 2020August 13, 2020

Seelos to Proceed With Phase 2b/3 Trial Investigating SLS-005 for ALS

News

Seelos Therapeutics has received a notification from the U.S. Food and Drug Administration (FDA) permitting the launch of its Phase 2b/3 clinical trial investigating SLS-005 (trehalose) as a treatment ... Read more

July 9, 2020July 9, 2020

QurAlis Licenses Eli Lilly’s Preclinical Compounds That Target Neuronal Excitotoxicity

News

QurAlis Corporation has licensed preclinical small molecule compounds — designed to treat amyotrophic lateral sclerosis (ALS) — from Eli Lilly and Company, furthering QurAlis’s specialization in ALS treatment development. ... Read more

June 19, 2020June 19, 2020

NIH Grant Supports Work Into Cause of TDP-43 Protein Clumps in ALS, Alzheimer’s

News

The National Institutes of Health (NIH) has awarded a $3.3 million grant to researchers at two universities to advance studies of TDP-43, a protein that builds to form toxic clumps ... Read more

April 13, 2020June 2, 2020

Potential Stem Cell Therapy for ALS Moving into Phase 3 Trial

News

Seneca Biopharma announced that work is underway to advance NSI-566, its leading stem cell treatment candidate, into a Phase 3 study in people with amyotrophic lateral sclerosis (ALS). The decision followed a ... Read more

February 12, 2020February 20, 2020

ALS Combination Therapy PrimeC Receives FDA’s Orphan Drug Designation, Enters Clinical Trials

News

PrimeC, a new combination treatment by NeuroSense Therapeutics to slow down or halt the progression of amyotrophic lateral sclerosis (ALS), has received orphan drug status from the U.S. Food ... Read more

Pin It on Pinterest